Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer

Description

This randomized phase II trial studies how well veliparib and atezolizumab work either alone or in combination in treating patients with stage III-IV triple negative breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. It is not known whether giving veliparib and atezolizumab either alone or in combination would work better in patients with triple negative breast cancer.

Study Start Date

November, 15 2016

Estimated Completion Date

August 2018

Interventions

  • Drug: Atezolizumab
  • Drug: Veliparib
  • Other: Laboratory Biomarker Analysis

Study ID

National Cancer Institute (NCI) -- NCI-2016-01130

Status

Recruiting

Trial ID

NCT02849496

Study Type

Interventional

Trial Phase

Phase 2

Enrollment Quota

90

Sponsor

National Cancer Institute (NCI)

Inclusion Criteria

  • Patients must have histologically documented unresectable stage III or IV triple negative breast cancer (TNBC) and a known BRCA 1/2 mutation present
  • TNBC patients must be Her-2 negative, estrogen receptor (ER) negative (defined as less than 1% ER by immunohistochemistry [IHC]) and progesterone receptor (PR) negative breast cancer (defined as less than 1% PR staining by IHC)
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • No more than 3 lines of prior therapy in the metastatic setting are allowed
  • Prior chemotherapy is allowed, including platinum therapy
  • patients must not have received chemotherapy for 4 weeks prior to the initiation of study treatment and must have recovery =< grade 1 from any adverse events from any prior chemotherapy (other than alopecia) patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatment
  • Prior radiation therapy is allowed
  • patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment patients who have received prior radiation to 50% or more of their total marrow volume will be excluded
  • Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose, and no history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) is allowed, provided the following is met: minimum of 2 weeks prior to cycle 1, day 1
  • patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled the use of corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) is allowed, provided the following is met: minimum of 6 weeks prior to cycle 1, day 1
  • Patients taking bisphosphonate therapy for symptomatic hypercalcemia are NOT allowed
  • use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
  • Prior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed
  • patients must not have received these therapies for 4 weeks prior to the initiation of study treatment and must have recovery =< grade 1 from any adverse events of these therapies (other than alopecia) prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody is NOT allowed
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy of greater than 6 months
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 8 g/dL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x upper limit of normal (ULN) if no liver metastasis
  • =< 5 x upper ULN if liver metastasis present
  • Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
  • Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation
  • patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)
  • Patients must have tumors determined to be easily accessible for biopsy and must be willing to have serial biopsies (with a third biopsy upon evidence of disease progression)
  • Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control
  • abstinence) prior to study entry, for the duration of study participation, and for at least 5 months (150 days) after the last dose of study agent should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 5 months (150 days) after completion of atezolizumab and/or ABT-888 administration
  • Ability to understand and the willingness to sign a written informed consent document
  • Subject is able to swallow and retain oral medication and does not have uncontrolled emesis
  • Patients crossing over from monotherapy to combination therapy do not have to be fully rescreened
  • however, they do need to meet performance status, organ function, and blood parameters and not meet any of the exclusion criteria
  • Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:
  • A stable regimen of highly active anti-retroviral therapy (HAART)
  • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
  • A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test

Exclusion Criteria

  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
  • Patients with known brain metastases should be excluded from this clinical trial except as those described below
  • Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions:
  • Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:
  • Evaluable or measurable disease outside the CNS
  • No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)
  • No history of intracranial hemorrhage or spinal cord hemorrhage
  • No ongoing requirement for dexamethasone for CNS disease
  • patients on a stable dose of anticonvulsants are permitted
  • No neurosurgical resection or brain biopsy within 28 days prior to cycle 1, day 1
  • Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:
  • Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study
  • No stereotactic radiation or whole-brain radiation within 28 days prior to cycle 1, day 1
  • Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids
  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 and atezolizumab
  • Prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis
  • cirrhosis fatty liver and inherited liver disease
  • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA
  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, lichen sclerosis, or glomerulonephritis
  • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
  • Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible
  • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
  • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
  • Rash must cover less than 10% of body surface area (BSA)
  • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
  • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors
  • high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • history of radiation pneumonitis in the radiation field (fibrosis) is permitted if recovered
  • Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab
  • Influenza vaccination should be given during influenza season only (approximately October to March)
  • patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study
  • breastfeeding should be discontinued if the mother is treated with ABT-888 and atezolizumab
  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1
  • Patients with active seizures or a history of uncontrolled seizure disorder, including focal or generalized seizure within the past year
  • Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (152)

Study Location Distance Name Phone Email
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
DanaFarber Cancer Institute - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Gerburg M Wulf 617-667-9925 None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Gerburg M Wulf 617-667-9925 None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Gerburg M Wulf 617-667-9925 None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Gerburg M Wulf 617-667-9925 None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Gerburg M Wulf 617-667-9925 None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Gerburg M Wulf 617-667-9925 None
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles Gerburg M Wulf 617-667-9925 None
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles Gerburg M Wulf 617-667-9925 None
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles Gerburg M Wulf 617-667-9925 None
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles Gerburg M Wulf 617-667-9925 None
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles Gerburg M Wulf 617-667-9925 None
Smilow Cancer Hospital Care Center at Saint Francis - Hartford, Connecticut 91.9 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care Center at Saint Francis - Hartford, Connecticut 91.9 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care Center at Saint Francis - Hartford, Connecticut 91.9 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care Center at Saint Francis - Hartford, Connecticut 91.9 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care Center at Saint Francis - Hartford, Connecticut 91.9 miles Patricia M LoRusso 203-785-5702 None
Medical Oncology and Hematology Group PCGuilford - Guilford, Connecticut 109.8 miles Patricia M LoRusso 203-785-5702 None
Medical Oncology and Hematology Group PCGuilford - Guilford, Connecticut 109.8 miles Patricia M LoRusso 203-785-5702 None
Medical Oncology and Hematology Group PCGuilford - Guilford, Connecticut 109.8 miles Patricia M LoRusso 203-785-5702 None
Medical Oncology and Hematology Group PCGuilford - Guilford, Connecticut 109.8 miles Patricia M LoRusso 203-785-5702 None
Medical Oncology and Hematology Group PCGuilford - Guilford, Connecticut 109.8 miles Patricia M LoRusso 203-785-5702 None
Charlotte Hungerford Hospital Center for Cancer Care - Torrington, Connecticut 110.4 miles Patricia M LoRusso 203-785-5702 None
Charlotte Hungerford Hospital Center for Cancer Care - Torrington, Connecticut 110.4 miles Patricia M LoRusso 203-785-5702 None
Charlotte Hungerford Hospital Center for Cancer Care - Torrington, Connecticut 110.4 miles Patricia M LoRusso 203-785-5702 None
Charlotte Hungerford Hospital Center for Cancer Care - Torrington, Connecticut 110.4 miles Patricia M LoRusso 203-785-5702 None
Charlotte Hungerford Hospital Center for Cancer Care - Torrington, Connecticut 110.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalWaterbury Care Center - Waterbury, Connecticut 115.7 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalWaterbury Care Center - Waterbury, Connecticut 115.7 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalWaterbury Care Center - Waterbury, Connecticut 115.7 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalWaterbury Care Center - Waterbury, Connecticut 115.7 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalWaterbury Care Center - Waterbury, Connecticut 115.7 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer CenterYaleNew Haven Hospital - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer CenterYaleNew Haven Hospital - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer CenterYaleNew Haven Hospital - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer CenterYaleNew Haven Hospital - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer CenterYaleNew Haven Hospital - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University Cancer Center LAO - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5944 patricia.lorusso@yale.edu
Yale University Cancer Center LAO - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5944 patricia.lorusso@yale.edu
Yale University Cancer Center LAO - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5944 patricia.lorusso@yale.edu
Yale University Cancer Center LAO - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5944 patricia.lorusso@yale.edu
Yale University - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5702 None
Yale University Cancer Center LAO - New Haven, Connecticut 119.2 miles Patricia M LoRusso 203-785-5944 patricia.lorusso@yale.edu
Smilow Cancer HospitalDerby Care Center - Derby, Connecticut 122.5 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalDerby Care Center - Derby, Connecticut 122.5 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalDerby Care Center - Derby, Connecticut 122.5 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalDerby Care Center - Derby, Connecticut 122.5 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalDerby Care Center - Derby, Connecticut 122.5 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalOrange Care Center - Orange, Connecticut 124.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalOrange Care Center - Orange, Connecticut 124.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalOrange Care Center - Orange, Connecticut 124.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalOrange Care Center - Orange, Connecticut 124.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer HospitalOrange Care Center - Orange, Connecticut 124.4 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterTrumbull - Trumbull, Connecticut 133.3 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterTrumbull - Trumbull, Connecticut 133.3 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterTrumbull - Trumbull, Connecticut 133.3 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterTrumbull - Trumbull, Connecticut 133.3 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterTrumbull - Trumbull, Connecticut 133.3 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterFairfield - Fairfield, Connecticut 139.1 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterFairfield - Fairfield, Connecticut 139.1 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterFairfield - Fairfield, Connecticut 139.1 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterFairfield - Fairfield, Connecticut 139.1 miles Patricia M LoRusso 203-785-5702 None
Smilow Cancer Hospital Care CenterFairfield - Fairfield, Connecticut 139.1 miles Patricia M LoRusso 203-785-5702 None
Montefiore Medical CenterEinstein Campus - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterWeiler Hospital - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterEinstein Campus - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterEinstein Campus - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterWeiler Hospital - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterEinstein Campus - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterWeiler Hospital - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterWeiler Hospital - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterWeiler Hospital - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Montefiore Medical CenterEinstein Campus - The Bronx, New York 176.6 miles Jesus D Anampa Mesias 718-904-2730 aecc@aecom.yu.edu
Johns Hopkins UniversitySidney Kimmel Cancer Center - Baltimore, Maryland 356.0 miles Roisin M Connolly 410-955-8804 jhcccro@jhmi.edu
Johns Hopkins UniversitySidney Kimmel Cancer Center - Baltimore, Maryland 356.0 miles Roisin M Connolly 410-955-8804 jhcccro@jhmi.edu
Johns Hopkins UniversitySidney Kimmel Cancer Center - Baltimore, Maryland 356.0 miles Roisin M Connolly 410-955-8804 jhcccro@jhmi.edu
Johns Hopkins UniversitySidney Kimmel Cancer Center - Baltimore, Maryland 356.0 miles Roisin M Connolly 410-955-8804 jhcccro@jhmi.edu
Johns Hopkins UniversitySidney Kimmel Cancer Center - Baltimore, Maryland 356.0 miles Roisin M Connolly 410-955-8804 jhcccro@jhmi.edu
University of Pittsburgh Cancer Institute UPCI - Pittsburgh, Pennsylvania 477.2 miles Adam M Brufsky 353-129-3669 None
University of Pittsburgh Cancer Institute UPCI - Pittsburgh, Pennsylvania 477.2 miles Adam M Brufsky 353-129-3669 None
University of Pittsburgh Cancer Institute UPCI - Pittsburgh, Pennsylvania 477.2 miles Adam M Brufsky 353-129-3669 None
University of Pittsburgh Cancer Institute UPCI - Pittsburgh, Pennsylvania 477.2 miles Adam M Brufsky 353-129-3669 None
University of Pittsburgh Cancer Institute UPCI - Pittsburgh, Pennsylvania 477.2 miles Adam M Brufsky 353-129-3669 None
Case Western Reserve University - Cleveland, Ohio 544.0 miles Shaveta Vinayak 800-641-2422 None
Case Western Reserve University - Cleveland, Ohio 544.0 miles Shaveta Vinayak 800-641-2422 None
Case Western Reserve University - Cleveland, Ohio 544.0 miles Shaveta Vinayak 800-641-2422 None
Case Western Reserve University - Cleveland, Ohio 544.0 miles Shaveta Vinayak 800-641-2422 None
Ohio State University Comprehensive Cancer Center - Columbus, Ohio 641.8 miles Anne M Noonan 800-411-1222 None
Ohio State University Comprehensive Cancer Center - Columbus, Ohio 641.8 miles Anne M Noonan 800-411-1222 None
Ohio State University Comprehensive Cancer Center - Columbus, Ohio 641.8 miles Anne M Noonan 800-411-1222 None
Ohio State University Comprehensive Cancer Center - Columbus, Ohio 641.8 miles Anne M Noonan 800-411-1222 None
Ohio State University Comprehensive Cancer Center - Columbus, Ohio 641.8 miles Anne M Noonan 800-411-1222 None
Vanderbilt UniversityIngram Cancer Center - Nashville, Tennessee 944.2 miles Vandana G Abramson 800-811-8480 None
Vanderbilt UniversityIngram Cancer Center - Nashville, Tennessee 944.2 miles Vandana G Abramson 800-811-8480 None
Vanderbilt UniversityIngram Cancer Center - Nashville, Tennessee 944.2 miles Vandana G Abramson 800-811-8480 None
Vanderbilt UniversityIngram Cancer Center - Nashville, Tennessee 944.2 miles Vandana G Abramson 800-811-8480 None
Vanderbilt UniversityIngram Cancer Center - Nashville, Tennessee 944.2 miles Vandana G Abramson 800-811-8480 None
Washington University School of Medicine - Saint Louis, Missouri 1,039.5 miles Haeseong Park 800-600-3606 info@siteman.wustl.edu
Washington University School of Medicine - Saint Louis, Missouri 1,039.5 miles Haeseong Park 800-600-3606 info@siteman.wustl.edu
Washington University School of Medicine - Saint Louis, Missouri 1,039.5 miles Haeseong Park 800-600-3606 info@siteman.wustl.edu
Mayo Clinic - Rochester, Minnesota 1,083.1 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic - Rochester, Minnesota 1,083.1 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic - Rochester, Minnesota 1,083.1 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic - Rochester, Minnesota 1,083.1 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic - Rochester, Minnesota 1,083.1 miles Ciara C OSullivan 855-776-0015 None
Moffitt Cancer Center - Tampa, Florida 1,178.7 miles Hyo S Han 800-456-7121 canceranswers@moffitt.org
Moffitt Cancer Center - Tampa, Florida 1,178.7 miles Hyo S Han 800-456-7121 canceranswers@moffitt.org
Moffitt Cancer Center - Tampa, Florida 1,178.7 miles Hyo S Han 800-456-7121 canceranswers@moffitt.org
Moffitt Cancer Center - Tampa, Florida 1,178.7 miles Hyo S Han 800-456-7121 canceranswers@moffitt.org
Moffitt Cancer Center - Tampa, Florida 1,178.7 miles Hyo S Han 800-456-7121 canceranswers@moffitt.org
University of Colorado Hospital - Aurora, Colorado 1,759.8 miles Anosheh Afghahi 720-848-0650 None
University of Colorado Hospital - Aurora, Colorado 1,759.8 miles Anosheh Afghahi 720-848-0650 None
University of Colorado Hospital - Aurora, Colorado 1,759.8 miles Anosheh Afghahi 720-848-0650 None
University of Colorado Hospital - Aurora, Colorado 1,759.8 miles Anosheh Afghahi 720-848-0650 None
University of Colorado Hospital - Aurora, Colorado 1,759.8 miles Anosheh Afghahi 720-848-0650 None
Mayo Clinic in Arizona - Scottsdale, Arizona 2,280.6 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic in Arizona - Scottsdale, Arizona 2,280.6 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic in Arizona - Scottsdale, Arizona 2,280.6 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic in Arizona - Scottsdale, Arizona 2,280.6 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic in Arizona - Scottsdale, Arizona 2,280.6 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic Hospital - Phoenix, Arizona 2,284.5 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic Hospital - Phoenix, Arizona 2,284.5 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic Hospital - Phoenix, Arizona 2,284.5 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic Hospital - Phoenix, Arizona 2,284.5 miles Ciara C OSullivan 855-776-0015 None
Mayo Clinic Hospital - Phoenix, Arizona 2,284.5 miles Ciara C OSullivan 855-776-0015 None
UC San Diego Moores Cancer Center - La Jolla, California 2,581.5 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
UC San Diego Moores Cancer Center - La Jolla, California 2,581.5 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
UC San Diego Moores Cancer Center - La Jolla, California 2,581.5 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
UC San Diego Moores Cancer Center - La Jolla, California 2,581.5 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
UC San Diego Moores Cancer Center - La Jolla, California 2,581.5 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California San Diego - San Diego, California 2,582.6 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California San Diego - San Diego, California 2,582.6 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California San Diego - San Diego, California 2,582.6 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California San Diego - San Diego, California 2,582.6 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California San Diego - San Diego, California 2,582.6 miles Erin Roesch 858-822-5354 cancercto@ucsd.edu
University of California Davis Comprehensive Cancer Center - Sacramento, California 2,628.4 miles None None None
University of California Davis Comprehensive Cancer Center - Sacramento, California 2,628.4 miles None None None
University of California Davis Comprehensive Cancer Center - Sacramento, California 2,628.4 miles None None None
University of California Davis Comprehensive Cancer Center - Sacramento, California 2,628.4 miles None None None
University of California Davis Comprehensive Cancer Center - Sacramento, California 2,628.4 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.